killed oral cholera vaccine
A cholera vaccine is a vaccine that is effective at reducing the risk of contracting cholera. The recommended cholera vaccines are administered orally to elicit local immune responses in the gut, where the intestinal cells produce antibodies against Vibrio cholerae, the bacteria responsible for the illness. This immune response was poorly achieved with the injectable vaccines that were used until the 1970s. The first effective oral cholera vaccine was Dukoral, developed in Sweden in the 1980s. For the first six months after vaccination it provides about 85% protection, which decreases to approximately 60% during the first two years. When enough of the population is immunized, it may protect those who have not been immunized thereby increasing the total protective impact to more than 90 %. — Wikipedia
Clinical trial activity
29 trials · 38 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2005 (NCT00128011)
Timeline
Indications
Approved for
Studied for
- Cholera · Phase 4
- Cholera Vaccines · Phase 2
- Colitis, Ulcerative · Phase 2
- Diarrhea · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Immunity · Phase 4
- Infections · Phase 1
- Kidney Transplantation · Phase 4
- Measles · Phase 3
- Primary Prevention · Phase 3
- Rubella · Phase 3
- Typhoid Fever · Phase 4
- Vaccine-Preventable Diseases · Phase 4
- Vaccines · Phase 3
- Vibrio cholerae · Phase 4
- Vibrio Infections · Phase 3
Mechanism of action
- Vibrio choleraeImmunity, active
Vibrio cholerae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCholera vaccine ↗
Also known as
- bivalent killed oral cholera vaccine
- bivalent killed whole cell oral cholera vaccine
- dukoral
- euvichol
- killed oral cholera vaccine
- killed whole cell oral cholera vaccine
- oral cholera vaccine
- whole cell killed cholera vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07270796 | Phase 1 | Dec 31, 2025 | International Vaccine Institute |
| NCT07304284 | Phase 3 | Oct 31, 2025 | BioVac, International Vaccine Institute, Medical Research Council, South Africa |
| NCT06104345 | Phase 4 | Oct 31, 2023 | University of Helsinki |
| NCT05771779 | Phase 3 | Oct 14, 2023 | Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research |
| NCT05732766 | Phase 3 | Feb 4, 2023 | Bharat Biotech International Limited |
| NCT05453253 | Phase 4 | Jul 20, 2022 | Epicentre, Government of the Republic of Guinea, Harvard University, Medecins Sans Frontieres |
| NCT05507229 | Phase 3 | Feb 22, 2022 | Bharat Biotech International Limited |
| NCT04760236 | Phase 3 | May 20, 2021 | EuBiologics Co.,Ltd, International Vaccine Institute |
| NCT03719066 | Phase 2 | Oct 23, 2018 | Bill and Melinda Gates Foundation, Johns Hopkins University, Meilleur Accès aux Soins de Santé (M.A. Santé) |
| NCT03581734 | Phase 3 | Jul 1, 2018 | Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research, Stanford University |
| NCT03373669 | Phase 4 | Nov 16, 2017 | Johns Hopkins University |
| NCT04423159 | N/A | Oct 16, 2016 | Centre for Infectious Disease Research in Zambia (CIDRZ), European and Developing Countries Clinical Trials Partnership (EDCTP), Johns Hopkins University |
| NCT02823899 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Bill and Melinda Gates Foundation, International Center for Diarrheal Disease Research |
| NCT02502331 | Phase 3 | Mar 1, 2016 | EuBiologics Co.,Ltd, International Vaccine Institute |
| NCT00548054 | Phase 2 | Dec 1, 2015 | Indian Council of Medical Research, International Vaccine Institute, National Institute of Cholera and Enteric Diseases, Kolkata, India, National Institutes of Health (NIH), Shantha Biotechnics Limited |
| NCT02164110 | Phase 3 | May 1, 2014 | De La Salle University, EuBiologics Co.,Ltd, Instituto Universitario IVI |
| NCT01524640 | Phase 4 | Dec 1, 2012 | Armauer Hansen Research Institute, Ethiopia, Government of Ethiopia, International Vaccine Institute, Shantha Biotechnics Limited |
| NCT01707537 | Phase 1 | Sep 1, 2012 | Chungnam National University, EuBiologics Co.,Ltd, Instituto Universitario IVI |
| NCT00760825 | Phase 4 | Mar 1, 2012 | Christian Medical College, Vellore, India, International Vaccine Institute, Shantha Biotechnics Limited |
| NCT01233362 | Phase 2 | Dec 1, 2010 | Indian Council of Medical Research, International Vaccine Institute, National Institute of Cholera and Enteric Diseases, Kolkata, India, Shantha Biotechnics Limited |